Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THN201 vs Donepezil in Healthy Males with Scopolamine Challenge
NCT03698695Phase 1Completed
- Sponsor
- Theranexus
- Start
- Sep 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of THN201 in Alzheimer's disease (AD) (3 arms), sponsored by Theranexus. Primary endpoint: Cognitive function measured with the Cognitive Drug Research (CDR) test battery at 15 days. Started Sep 2018; status: completed.
02
Drugs
THN201
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03698695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03698695.